Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time ...

Combining SBRT with GM-CSF and peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors: A single arm, single center, phase II trial.

Tolerance Bio is targeting an often-overlooked organ — the thymus — with cell therapy to help kids with DiGeorge syndrome, and potentially extend lifespan in adults.

Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors. Comparing impact of treatment before or after surgery in ...

Data from the WAYFINDER study showed clinically meaningful reductions and discontinuations of oral corticosteroids.

A panelist discusses how NCCN guidelines now include cabozantinib as a category 1 recommendation for gastrointestinal (GI) ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...

Background Minimally invasive approaches, including video-assisted thoracoscopic thymectomy (VATT) and robot-assisted thoracoscopic thymectomy (RATT), have emerged as alternatives to median sternotomy ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal ...

Teva Pharmaceutical Industries Ltd. has commenced IND-enabling studies with BD-9, a dual-specific multibody targeting thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). By simultaneously ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Discover a study that found that tezepelumab also showed promise in patients previously unresponsive to other biologics.